KYNB - Kyntra Bio, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

KYNB

KYNTRA BIO, INC.

NASDAQ

$8.02

▲ UP 0.25% (0.02)

KEY STATISTICS

Market Cap$32.47 M

52w High$12.60

52w Low$6.32

Dividend Yield—

Frequency—

P/E-0.65

Volume15.78K

Shares Out.4.05M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Thane Wettig

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 14, 2014

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$28.00

Target Low$28.00

Target Median$28.00

Target Consensus$28.00

UPCOMING EARNINGS

DateNov 9, 2026

DayMonday

Rev. Est.$1.97M

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2025-06-17	Reverse	1:25

PRICE

$8.02 ▲ UP 0.25% (+$0.02)

OVERLAYS

About Kyntra Bio, Inc.

https://www.kyntrabio.com ↗

Kyntra Bio, Inc. is a San Francisco-based biopharmaceutical company developing novel therapeutics targeting hypoxia-inducible factor and connective tissue growth factor for anemia, fibrotic disease, and cancer.

INDUSTRY

Biotechnology

A PRODUCT KYNTRA BIO, INC. IS KNOWN FOR

FG-3246

FG-3246 is a Phase 2 antibody-drug conjugate by Kyntra Bio targeting metastatic castration-resistant prostate cancer, marking the company's main focus in oncology.

COMPETITORS

COMPETITOR

Revenue by Products

Icon	PRODUCT	Q3-2025	Q4-2025	Q1-2026	Q2-2026
	Drug Product Revenue	$957K	$1.08M ▲	$3.49M ▲	-$1.58M ▼

Revenue by Geography

REGION	FY2022	FY2023	FY2024	FY2025
UNITED STATES	$12.52M	$12.96M ▲	$26.11M ▲	—
Europe	$33.82M	$9.55M ▼	$6.27M ▼	$5.64M ▼
JAPAN	$9.76M	$15.87M ▲	-$2.85M ▼	$797K ▲
CHINA	$84.63M	$109.38M ▲	$91K ▼	—